RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC
(MedPage Today) -- MADRID -- First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Thyroid | Thyroid Cancer